Prestige BioPharma Reports Revenue Growth but Continues Operating Loss; Net Loss Widens Due to Impairment on Subsidiary Investment
Consolidated cumulative revenue for the period (2025.07~2026.03) was USD 7,459,096, up 18.8% from USD 6,277,007 in the same period last year, but operating loss widened to USD 49,094,315.
On a separate basis, the company recognized an impairment loss of USD 66,139,687 on its investment in subsidiary Prestige Biologics, resulting in a net loss of USD 76,503,485, a sharp swing from net profit a year ago.
Consolidated net loss was USD 49,275,954, compared to a net profit of USD 9,462,557 in the prior year period, mainly due to the absence of a USD 42,400,421 impairment reversal on HD201 intangible assets that boosted prior year results.
Cash and cash equivalents decreased to USD 41,910,626 from USD 85,061,607 at the end of the previous fiscal year, a decline of about 50%. Operating cash flow was negative USD 25,741,872. Total borrowings fell 46.6% to USD 56,788,323.
HD201 (Tuznue) received EU marketing authorization and signed supply agreements with Teva and others for Europe and Latin America, with initial exports commenced. HD204 (bevacizumab biosimilar) completed global Phase 3 trials and is in follow-up procedures.
R&D expenditure was USD 23,555,875, representing 313.3% of revenue, maintaining a high level of investment. Key pipeline PBP1510 (pancreatic cancer antibody) is in global Phase 1/2a.
No dividends were paid, and there are no plans for share buybacks or cancellations.